Wells Fargo & Company Seres Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 31,394 shares of MCRB stock, worth $22,603. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,394
Previous 27,992
12.15%
Holding current value
$22,603
Previous $39,000
38.46%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding MCRB
# of Institutions
100Shares Held
62.7MCall Options Held
36.9KPut Options Held
476K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$16.6 Million1.17% of portfolio
-
Black Rock Inc. New York, NY6.83MShares$4.91 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.73MShares$4.85 Million0.0% of portfolio
-
Hudson Bay Capital Management LP Greenwich, CT5.43MShares$3.91 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA2.13MShares$1.54 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $89.3M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...